Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
7.42
-0.09 (-1.20%)
Jul 17, 2026, 4:00 PM EDT - Market closed
Instil Bio Employees
Instil Bio had 17 employees as of December 31, 2025. The number of employees increased by 3 or 21.43% compared to the previous year.
Employees
17
Change (1Y)
3
Growth (1Y)
21.43%
Revenue / Employee
n/a
Profits / Employee
-$2,786,824
Market Cap
50.32M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 14 | -35 | -71.43% |
| Dec 31, 2023 | 49 | -143 | -74.48% |
| Dec 31, 2022 | 192 | -220 | -53.40% |
| Jun 30, 2022 | 463 | 156 | 50.81% |
| Mar 31, 2022 | 437 | 195 | 80.58% |
| Dec 31, 2021 | 412 | 262 | 174.67% |
| Sep 30, 2021 | 382 | 232 | 154.67% |
| Jun 30, 2021 | 307 | - | - |
| Mar 31, 2021 | 242 | - | - |
| Dec 31, 2020 | 150 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xilio Therapeutics | 76 |
| Seres Therapeutics | 66 |
| aTyr Pharma | 60 |
| BeyondSpring | 44 |
| Mereo BioPharma Group | 39 |
| eXoZymes | 32 |
| INmune Bio | 21 |
| Filana Therapeutics | 20 |
TIL News
- 2 months ago - Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Instil Bio downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 6 months ago - Baird downgrades Instil Bio on discontinuation of AXN-2510 - TheFly
- 6 months ago - Instil Bio downgraded to Neutral from Outperform at Baird - TheFly
- 6 months ago - Instil Bio’s Axion discontinues clinical development of AXN-2510 - TheFly
- 6 months ago - Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco - GlobeNewsWire
- 8 months ago - Instil Bio reports Q3 EPS ($1.75) vs ($2.55) last year - TheFly